17 news items
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
ARVN
17 Jun 24
biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President
Arvinas to Participate in Upcoming Investor Conferences
ARVN
3 Jun 24
biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
ARVN
23 May 24
oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer's atirmociclib (PF-07220060), an investigational
Analyst Ratings For Arvinas
ARVN
17 May 24
In the assessment of 12-month price targets, analysts unveil insights for Arvinas, presenting an average target
HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target
ARVN
17 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $87 price target.
uqert4ajr l4q
ARVN
ASTS
BA
16 May 24
. (NASDAQ:MGNI) climbed 21.6% to $11.91. Needham analyst Laura Martin reiterated Magnite with a Buy and maintained a $15 price target
jkx3ff676i10jqe026gxd63p3cq68e15th1m
ARVN
PFE
16 May 24
cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader
d465dxhr xtu43gp
ARQT
ARVN
BCRX
15 May 24
and raised its price target from $12 to $14.
Shift4 Payments, Inc
wpkef6mi hu8
ARVN
9 May 24
Poster Title and Number: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor
amvrs9lzbhvn4phcxsehvrxhjc 57gv4fwt47mn3
ARVN
9 May 24
Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $63 to $60.
rcg rioxuvoabv2bkz77rfvs
ARVN
8 May 24
Wedbush analyst Robert Driscoll reiterates Arvinas (NASDAQ:ARVN) with a Outperform and maintains $57 price target.
ueghz m1rp8zbu54j4rjte4fryzey5kntwtzmzc07girpuvj9og32y2i
ARVN
8 May 24
Stifel analyst Bradley Canino maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $72 to $68.
itszwogrk
ARVN
8 May 24
HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:ARVN) with a Buy and maintains $87 price target.
4m9deten1znbo1kmz9apj1nusdied718ppfcp0d0
ARVN
NVS
7 May 24
class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2024 and provided
ke6ce29
ARVN
2 May 24
biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming
ozll46ozika51hjm1x94ilxexl4imyx1hsqv7ukcbmpfm28q5wp
ARVN
ATOS
ICCM
30 Apr 24
is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed
3hzlk 8wx
ARVN
ATOS
ICCM
30 Apr 24
, which is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed
- Prev
- 1
- Next